贝伐单抗作为抗 VEGFR 通路的药物应用于肺癌临床治疗价值分析  

Clinical application value of bevacizumab as anti-VEGFR pathway drug in lung cancer

作　　者：陈瑞琳[1] 张程程[1] 张永庆[1] 吴桦[1] 杨淑梅[1] 

机构地区：[1]陕西省人民医院呼吸内科,西安710068

出　　处：《国际呼吸杂志》2016年第18期1372-1375,共4页International Journal of Respiration

摘　　要：目的：探讨贝伐单抗联合化疗应用于肺癌临床治疗的价值。方法选取2015年1月至2016年1月在我院治疗的晚期非鳞癌非小细胞肺癌患者60例,将患者分为观察组（n =30）和对照组（n =30）。观察组接受贝伐单抗联合培美曲塞加铂类方案化疗,对照组接受培美曲塞加铂类方案,观察2组治疗疗效。结果观察组肿瘤客观缓解率为53.33%,明显高于对照组（26.67%）,差异有统计学意义（χ2=4.444,P 〈0.05）；观察组和对照组临床获益率分别为80.00%和63.33%,差异无统计学意义（χ2=2.052,P 〉0.05）；观察组中位生存期为13个月（95% CI ：9.99-14.51）,对照组中位生存期为10个月（95% CI ：9.05-11.95）,2组中位生存期比较差异有统计学意义（χ2=5.255,P 〈0.05）；观察组出现高血压症状的比例为26.67%,明显高于对照组（3.33%）,差异有统计学意义（χ2=6.405,P 〈0.05）,其余不良反应比较差异均无统计学意义（P 值均〉0.05）。结论贝伐单抗联合化疗治疗非鳞癌非小细胞肺癌有较好的临床疗效,可延长患者生存时间。Objective To investigate value of bevacizumab combined with chemotherapy in the treatment of lung cancer.Methods 60 patients with advanced non squamous cell non-small cell lung cancer were selected,who were treated in our hospital from January 201 5 to January 201 6.The patients were divided into observation group（n =30）and control group（n =30）.The observation group received bevacizumab combined with pemetrexed plus platinum chemotherapy,the control group received pemetrexed plus platinum chemotherapy.The curative effect of the two groups were observed.Results The tumor objective remission rate of observation group was 53.33%,which was significantly higher than that of control group（26.67%,χ2=4.444,P 〈0.05）.The clinical benefit rates of observation group and control group were 80.00% and 63.33%,the difference was not statistically significant（χ2=2.052,P 〉0.05）.The median survival time of observation group was 13 months （95% CI ：9.99-14.5 1）,median survival time of control group was 10 months （95% CI ：9.05-1 1.95）,the difference was statistically significant（χ2 =5.255,P 〈0.05）.The proportion of hypertension symptoms in the observation group was 26.67%,significantly higher than that in the control group （3.33%,χ2 =6.405,P 〈0.05）.There was no statistical significance in the other adverse reactions between the two groups （all P 〉 0.05）. Conclusions Bevacizumab combined chemotherapy has better clinical efficacy and prolong survival time for non squamous cell non-small cell lung cancer.

关 键 词：贝伐单抗 非鳞癌非小细胞肺癌 联合化疗 

分 类 号：R734.2[医药卫生—肿瘤]